Immunovia AB (FRA:1YR) Marketable Securities: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1YR Immunovia AB FRA:1YR
41 GF Score
Price €0.01
GF Value €0.01
! 6 Warning Signs
View Full Analysis

What is Immunovia AB Marketable Securities?

Immunovia AB FRA:1YR 41 Marketable Securities is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:1YR with a GF Score™ of 41/100 and a GF Value™ of €0.01. The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Immunovia AB's Marketable Securities for the quarter that ended in Jun. 2026 was €0.00 Mil.

Immunovia AB  (FRA:1YR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Immunovia AB Marketable Securities Related Terms

Immunovia AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Marketable Securities Chart

Immunovia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Immunovia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1YR
41GF Score
Immunovia AB FRA:1YR
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Immunovia AB (FRA:1YR) has a Marketable Securities of €0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Immunovia AB and its competitors.
Is Immunovia AB's Marketable Securities too high?
Immunovia AB's current Marketable Securities is €0.00 Mil. Overall, Immunovia AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Marketable Securities compare to TMO and DHR?
Immunovia AB's Marketable Securities of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Immunovia AB and its competitors. Immunovia AB's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (FRA:1YR) has a current Marketable Securities of €0.00 Mil. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 3% below its estimated fair value. The current Marketable Securities is €0.00 Mil. Immunovia AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Immunovia AB (FRA:1YR), the current Marketable Securities is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunovia AB (FRA:1YR) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be undervalued. The current stock price of €0.01 is trading 3% below its estimated GF Value™ of €0.01.

Key valuation signals for FRA:1YR:

  • Marketable Securities: €0.00 Mil
  • GF Value™: €0.01 vs. price of €0.01 (3% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the FRA:1YR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges IMMNOV:Sweden0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
41GF Score

Get the complete analysis for FRA:1YR

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price
€0.01
GF Value